Literature DB >> 15841321

Mycobacterium tuberculosis inducing disseminated intravascular coagulation.

Jann-Yuan Wang1, Po-Ren Hsueh, Li-Na Lee, Yuang-Shuang Liaw, Wen-Yi Shau, Pan-Chyr Yang, Kwen-Tay Luh.   

Abstract

Disseminated intravascular coagulation (DIC) can develop infrequently in patients with tuberculosis and has a very high mortality rate. We conducted a retrospective study to evaluate the incidence of tuberculosis-induced DIC and to investigate the clinical manifestation, outcome, and prognostic factors of such patients. From January 2002 to December 2003, all culture-proven tuberculosis patients who developed DIC before starting anti-tuberculosis treatments were selected for this study. Patients who had other clinical conditions or were infected by other pathogens that may have been responsible for their DIC were excluded. Survival analysis was performed for each variable with possible prognostic significance. Our results showed that 27 (3.2%) out of the 833 patients with culture-proven tuberculosis had tuberculosis-induced DIC with a mortality rate of 63.0%. The most common clinical manifestations were fever (63.0%) and multiple patches of pulmonary consolidation (59.3%). Seven (25.9%) patients had disseminated tuberculosis. Twelve (44.4%) developed acute respiratory distress syndrome and three (11.1%) were associated with hemophagocytosis. Twenty-four (88.9%) patients had findings that were unusual for an acute bacterial infection, such as positive acid-fast smear, miliary pulmonary lesions, lymphocytotic exudative pleural effusion, and mediastinal lymphadenopathy. Early anti-tuberculosis treatment significantly improved survival. In conclusion, tuberculosis can cause DIC. Patients with non-miliary, non-disseminated tuberculosis could also develop the rare clinical manifestation. Since the prognosis was very poor in patients not treated at an early stage, a high index of suspicion is required, especially in those with clinical findings suggestive of tuberculosis.

Entities:  

Mesh:

Year:  2005        PMID: 15841321     DOI: 10.1160/TH04-09-0562

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

1.  Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas.

Authors:  J-Y Wang; P-R Hsueh; I-S Jan; L-N Lee; Y-S Liaw; P-C Yang; K-T Luh
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

2.  Performance assessment of the CapitalBio mycobacterium identification array system for identification of mycobacteria.

Authors:  Jingbo Liu; Jun Yue; Zihe Yan; Min Han; Zhijun Han; Lingjie Jin; Yanlin Zhao
Journal:  J Clin Microbiol       Date:  2011-11-16       Impact factor: 5.948

3.  Elderly onset systemic lupus erythematosus (SLE) presenting with disseminated intravascular coagulation (DIC).

Authors:  Masayuki Iyoda; Hiroki Suzuki; Eijin Ashikaga; Hisako Nagai; Aki Kuroki; Takanori Shibata; Kozo Kitazawa; Tadao Akizawa
Journal:  Clin Rheumatol       Date:  2007-12-19       Impact factor: 2.980

4.  Performance assessment of the DR. MTBC Screen assay and the BD ProbeTec ET system for direct detection of Mycobacterium tuberculosis in respiratory specimens.

Authors:  Jann-Yuan Wang; Li-Na Lee; Hsiao-Leng Hsu; Po-Ren Hsueh; Kwen-Tay Luh
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

5.  Mycobacterium tuberculosis infection and tissue factor expression in macrophages.

Authors:  Hema Kothari; L Vijaya Mohan Rao; Ramakrishna Vankayalapati; Usha R Pendurthi
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

6.  Expression and Purification of Recombinant Mycobacterium Tuberculosis (TB) Antigens, ESAT-6, CFP-10 and ESAT- 6/CFP-10 and Their Diagnosis Potential for Detection of TB Patients.

Authors:  M Hemmati; A Seghatoleslam; M Rasti; S Ebadat; N Mosavari; M Habibagahi; M Taheri; A R Sardarian; Z Mostafavi-Pour
Journal:  Iran Red Crescent Med J       Date:  2011-08-01       Impact factor: 0.611

7.  Phenylbutyrate Is Bacteriostatic against Mycobacterium tuberculosis and Regulates the Macrophage Response to Infection, Synergistically with 25-Hydroxy-Vitamin D3.

Authors:  Anna K Coussens; Robert J Wilkinson; Adrian R Martineau
Journal:  PLoS Pathog       Date:  2015-07-02       Impact factor: 6.823

8.  Role of tissue factor in Mycobacterium tuberculosis-induced inflammation and disease pathogenesis.

Authors:  Hema Kothari; Shiva Keshava; Rit Vatsyayan; Nigel Mackman; L Vijaya Mohan Rao; Usha R Pendurthi
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

9.  Diagnosis of tuberculosis by an enzyme-linked immunospot assay for interferon-gamma.

Authors:  Jann-Yuan Wang; Chien-Hong Chou; Li-Na Lee; Hsiao-Leng Hsu; I-Shiow Jan; Po-Ren Hsueh; Pan-Chyr Yang; Kwen-Tay Luh
Journal:  Emerg Infect Dis       Date:  2007-04       Impact factor: 6.883

Review 10.  Do COVID-19 Infections Result in a Different Form of Secondary Hemophagocytic Lymphohistiocytosis.

Authors:  Raymond Chu; Charmaine van Eeden; Sneha Suresh; Wendy I Sligl; Mohammed Osman; Jan Willem Cohen Tervaert
Journal:  Int J Mol Sci       Date:  2021-03-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.